A Review on an Introduction to the Synthetic Method and Pharamcological Acitvity of Oxadiazole Nucleus
Priyanka1, Lalita Tyagi2, Priyanshu3
1Professor, Kalka Institute for Research and Advanced Studies, Meerut, Uttar Pradesh, India.
2Assistant Professor, Kalka Institute for Research and Advanced Studies, Meerut, Uttar Pradesh, India.
3Assistant Professor, Meerut Institute of Technology, Meerut, Uttar Pradesh, India.
*Corresponding Author E-mail: priya.its05@gmail.com, tyagilalita55@gmail.com
ABSTRACT:
1,3,4-Oxadiazole derivatives are one of the important nitrogen-containing heterocycles which has received growing attention in recent past because for their diverse biological activities. In this review, the most recent advances in the discovery of their therapeutic potential are addressed. literature witnessing the efficiency of 1,3,4-oxadiazole derivatives against different biological targets, as anticancer, antimicrobial, antidiabetic, anti-inflammatory and neuroprotective. These compounds have shown effective results especially against drug resistant pathogens, metabolic disorders and presented potential remedies for neurodegenerative diseases. 1,3,4-Oxadiazole derivatives have become prominently attractive in drug discovery and development due to their various biological activities. In this review, we summarize major findings from recent studies and provide an introduction to therapeutic applications and future directions. The features of their structure scaffolds make them attractive in the field drug discovery and medicinal chemistry.
INTRODUCTION:
Heterocycles are the almost commonly found chemical scaffolds researched in medicinal chemistry on account of their important contributions in group of medicines1. These are the basic units for many bioactive molecules which exhibit therapeutic activities2. Oxadiazole, a five-membered heterocyclic structure containing one oxygen atom, two nitrogen atoms and two double bonds3 are such a class of the system.
Because of its special electronic structure and stability, oxadiazole has become increasingly interesting in pharmaceutical studies4. In the last few years, a large number of research works have been carried out on oxadiazole derivatives to study their prospective therapeutic role in several pathological and pharmacological fields5.
Oxadiazole is a heterocyclic aromatic organic compound with the molecular formula C2H2N2O. It is a pentamer of 2 nitrogen atoms, 2 carbon atoms and1 oxygen atom and 2 double bonds6. It is related structurally to furan by replacement of two =CH-groups with 2 pyridinium equivalent nitrogen (=N-). Hence, 4 isomers of oxadiazole can exists depending upon the position by nitrogen atom in the ring as shown in Figure 1;
1,2,4-Oxadiazole, 1,2,5-oxadiazole and 1,3,4 - oxadiazole are recorded compounds in the literature but the isomer 1,2,3 is unstable at room temperature and converts to the diazoketone tautomer. 1,3,4-Oxadiazole derivatives have been known to possess various biological activities such as antibacterial, antitubercular, vasodilatory; antifungal; cytotoxic activity against a wide range of tumour cell lines; anti-inflammatory analgesic hypolipidemic anticancer and ulcerogenic8. The compounds also are pesticidal, ant anthelmintic agents. Figure 2.
Figure 2
The general structure-activity relationship (SAR) of oxadiazole derivatives highlights that the biological activity—especially antibacterial, antiviral, and anticancer effects—depends significantly on the substitution pattern and the nature of substituents attached to the oxadiazole ring.9
Key SAR Features:
Ring Substitutions: Alterations in ring A (usually the phenyl or substituted phenyl) are essential. 4-Phenol, 4-chloropyrazole or 5-indole substitutions are preferred for antibacterial activity, especially against Gram-positive bacteria including MRSA.
Isomers of 1,3,4-Oxadiazole: The 1,3,4-oxadiazole isomer has been extensively investigated for its healthier pharmacological duties such as antimicrobial antiviral anticancer and others.
EWG's: Substituents such as trifluoromethyl or halogen frequently afford improved activity and metabolic stability.
Bioavailability and Toxicity: Some of its derivatives having a good potential in terms of oral bioavailability, low toxicity and powerful in vitro activity against resistant strains such as MRSA.
Pharmacokinetics: Alterations can affect plasma protein binding, clearance, and volume of distribution and thereby in vivo efficacy.
Wide Spectrum: Although oxadiazoles are most potent against Gram-positive bacteria, a few compounds display in addition antiviral (e.g., Raltegravir) and anticancer (e.g., Zibotentan) activities.10
Figure 3
MARKETED PREPARATION OF OXADIAZOLE:
Oxadiazole derivatives are able to be discovered in the marketed drug like Raltegravir (antiretroviral i.e. agent against HIV), Ataluren (cystic fibrosis treatment), Tiodazosin, and antihypertensive drugs (Nesapidil) Figure4, Zabotentan is the in final stage of clinical trials as anti-cancer agents (Figure 2). Commercial products based on oxadiazole derivatives. There are several drugs that contain oxadiazoles and have multiple therapeutic applications, for example antiviral activities, anticancer property, antihypertensive effects and utility in curing cystic fibrosis. Typical examples of marketed drugs based on oxadiazole include.11
1-[4-(2-Methoxyphenyl)-1-piperazinyl]-3-[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]-2-propanol
Figure 4. NESAPIDIL ANTIHYPERTENSIVE DRUG
5-[€-1-(furan-2-yl)-2-(5-nitrofuran-2-yl)ethenyl]-1,3,4-oxadiazol-2-amine
Figure 5. Furamiazole (Antibiotic)
N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-salfonamide
Fig. 6 Anticancer Drug
N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide
Fig. 7 Raltegravir Antiretro Viral
[4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl][5-(methylsulfanyl)-1,3,4-oxadiazol-2-yl]methanone
Fig. 8 Tiodazocin Antihypertensive 1,3,4-oxadiazole based drugs in the market
Kerimov (2020) described synthesis of a novel series of 1,3,4-oxadiazoles from arylhydrazines and acid chlorides in friendly manner at room temperature using DMF or DMSO as solvent and triethylamine as base12. The reaction was performed at [temp and time]. After the reaction was finished, the mixture was purified by column chromatography and TLC analysed, IR characterized. The product yield of the target products were 33-60%, according to the nature and number of substituents on aromatic ring (Scheme 1).
Scheme 1. Schematic representation of the synthetic routes
Ansari et al. (2009) synthesized 2-substituted-1H-benzimidazole as starting material and carried out nucleophilic substitution reaction by the treatment of o-phenylenediamine (7) with carboxylic acid. This protocol afforded the compound (8). (8) was then afforded by nucleophilic substitution followed by ethyl (2-substituted-1H-benzimidazol-1-yl) acetate (9). The structure of compound (9) was characterized using Infrared Spectroscopy (IR), proton Nuclear Magnetic Resonance (1 H NMR) and elemental analysis. Reducing compound (9) with hydrazine hydrate, gave compound (10). Compound (10) was reacted with various aliphatic or aromatic carboxylic acids by using phosphoryl chloride, to give a final product of compound (11) Scheme 213
Scheme 2
Kowalewska et al. (2022) were reported on oxadiazole moiety-based furan compounds synthesized via ultrasound-assisted synthesis. 33 The synthesis of ethyl benzofuran-2-carboxylate (36) was also performed by a multistep method described in the protocol by Kowalewska et al. This was provided by the reaction of 34 with ethyl chloroacetate in the presence of KOH (Scheme3).
Scheme 3
Suman Bala et. al (2014) Synthesized 1,3,4-Oxadiazole Derivatives and Characterized and assessed Antimicrobial Potential Scheme 415
Scheme 4
Anti-inflammatory effect:
Harish Kumar et. to et al (2008) A new series of 1,3,4-oxadiazole/thiadiazol and 1,2,4-triazole derivatives of bipheny( Figure 9)-oxy acetic acid were prepared to generate a new class of compounds that could have anti-inflammatory activity analgesic property with lesser ulcerogenic potential. All the compounds have been tested for anti-inflammatory activity by carrageenan- induced rat paw oedema test method. The compounds with best anti-inflammatory activity were evaluated for analgesic, ulcerogenic and antioxidant activities. Among the tested compounds, 5-[(Biphenyl-4-yloxy) methyl]-2-(4-chlorophenyl)-1,3, - 4-oxadiazole were found to be more effective in carrageenan-induced rat paw oedema.16
5-[(Biphenyl-4-yloxy)methyl]-2-(4-chlorophenyl)-1,3,-4-oxadiazole
Fig. 9
Shashikant V et.al (2008) Design, Synthesis and Evaluation of Anti-inflammatory, Analgesic and Ulcerogenicity studies of Novel S-Substituted phenacyl-1,3,4-oxadiazole-2-thiol and Schiff bases of Diclofenac acid as Nonulcerogenic Derivatives. new compound 5-[2-(2,6-Dichloroanilino) benzyl]-S-(4-nitro phenacyl)-1,3,4-oxadiazole-2-thio Figure 10, out of 18, were found to have significant anti-inflammatory activity in the carrageenan induced rat paw oedema model, with significant analgesic activity in the acetic acid induced writhing model with no ulcerogenicity.17
5-[2-(2,6-Dichloroanilino) benzyl]-S-(4-nitro phenacyl)-1,3,4-oxadiazole-2-thio
Caution: A radical appears to be present
Figure 10
B. Jayashankar et.al (2009) Synthesised and pharmacological evaluate 1,3,4-oxadiazole bearing bis(heterocycle) derivatives as anti-inflammatory and analgesic agents. Among the list of compounds (7a–k) studied2-(((4,5-Dihydro-3-p-tolylisoxazol-5-yl) methoxy) methyl)-5- (2,4-dichlorophenyl)-1,3,4-oxadiazole Figure 11exhibited excellent activity comparable to ibuprofen and aspirin at the similar dosages.18
2-(((4,5-Dihydro-3-p-tolylisoxazol-5-yl)methoxy)methyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole
Figure 11
Ankita Rathore 2014 et. al The Design and Synthesis Benzimidazole Analogues having Oxadiazole as Selective COX-2 Inhibitor. Compound 1-((5-(4-Nitrophenyl)-1,3,4-oxadiazol-2-yl)methyl)-2- ((pyrimidin-2-ylthio)methyl)-1H-benzo[d]imidazole Figure 12 significantly inhibited COX-2 with IC50 value of 8.2 mM and protection in percent (68.4%)19
Figure 12
Husain, A., et. al (1998) Prepared new 1,3,4-Oxadiazole derivatives figure 13 and screened for their biological activities. The title compounds were studied for anti-inflammatory, analgesic, ulcerogenic and antibacterial activities. Furthermore, the results of current study revealed that cyclization of carboxylic moiety 3-(4-bromobenzoyl) propionic acid into new 1,3,4-oxadiazole nucleus led to enhanced anti-inflammatory and analgesic activities along with appreciably lesser ulcerogenic activity.20
Figure 13
Harish Rajak et.al (2010) Novel oxadiazole and oxadiazoline analogues Figure 14: design, synthesis and pharmacological evaluation as anti-inflammatory agents. The results of the present investigations have suggested markedly that the existence of indole nucleus in oxadiazole and oxadiazoline analogs bears a favorable effect on anti- inflammatory effects.21
Figure 14
Anti-bacterial activity:
Sampark S. Thakkar et.al (2017) Synthesized and MO studies of 1,2,4-Triazole and 1,3,4-oxadiazole analogues Figure 15 and tested in silico molecular docking studies evaluated as antimalarial as DHFR inhibitor and antimicrobial activities. It is to be noted that compound 5-(4-((thiophen-2-ylmethylene) amino)phenyl)-1, 3, 4-oxadiazole-2-thiolfused with 4-amino-5-(4-aminophenyl)-4H-1, 2, 4-triazole-3-thiol in this study did not show any appreciable anti-fungal activities.22
Figure 15
Ananda Kumar Dunga et. al (2022) Dual 1,2,3-triazole and 1,3,4-oxadiazole linked indazole based heterocyclic compounds (Figure 16) were designed and synthesized successfully using 3-bromo-1H-indazole to evaluate as potential antimicrobial agentsThe antibacterial analysis of compounds was carried out against three Gram- (+ve), one Gram-(− ve) bacterial strains and compound 2-(((1-(2Flurophenyl)-1H-1, 2, 3-triazol -4 yl)methyl)thio)-5-(1-methyl -1H-indazol -3 yl)-one exhibited the maximum inhibitory activity against B. subtilis at a similar MICs value of 4.8±0.01 µg/ mL whereas the minimum MIC values of S. aureus found to be reported at a concentration range of5.30 ±0.05 μg/mL respectively23
Dual 1,2,3-triazole and 1,3,4-oxadiazole linked indazole based heterocyclic compounds
Figure 16
A.H. Shridhar et. al (2016) Figure 17: 3,5-Bis (alkyl-1,3,4-oxadiazole-2-yl azo dyes were prepared using multi-step reaction pathway. The synthesized compounds were screened for their antimicrobial and in vitro antioxidant activity. The prepared compounds 3,5-Bis(alkyl-1,3,4-oxadiazol-2-yl) azo dye are biologically very active and it has definitely extremely promising to find out potent bioactive agents.24
Figure 17
Kahdr Alatawi 2024 et. al Synthesis of some new 1,3,4-oxadiazole functionalized pyrano [2,3-f] chromene derivatives Fig.18 and Fig.19 and evaluated their in vitro antimicrobial activity. The antibacterial activity of the synthesized compounds was tested against Gram(+ve) (Bacillus subtilis, Staphylo coccus aureus), Gram(- ve) bacteria (Escherichia coli, Pseudomonas aeruginosa) and yeast like fungi (Candida albicans). Figures 13 and 14 showed the strong antibacterial effect.25
Figure 18
Figure 19
Noha Ryad (2025) Design, synthesis of novel 2- (2-(4-bromophenyl) quinolin-4-yl)-1,3,4-Oxadiazole derivatives Figure 20 as potential anticancer and antimicrobial agents for In vitro and in silico studies. Antimicrobial minimum inhibitory concentration was assessed for the lead candidates against S. aureus, E. coli and C. albicans.26
Figure 20
ACE enzyme inhibitory activity:
Manjunath R et al (2025) designed, synthesized 2-butyl-4-chloroimidazole-based 1,3,4-oxadiazoles Figure 21 and bioevaluated these compounds for ACE inhibition, anticancer and antitubercular activities. The ACE enzyme inhibitory activity of the compounds prepared was determined; compounds 2‑butyl‑4‑chloro-1-((5-phenyl-1,3,4oxadiazole-(2-yI)methyl)− lH-imidazole-5‑yDmethanol have IC50 values were found to be 81.29 ±0.70 and 51.01±1.58µM, respectively.27
Figure 21
Desta Gebretekle Shiferaw et. al 2024 Design and synthesis, characterization, biological evaluation and molecular docking of new 1,3,4-oxadiazole-thioether Figure 22 derivative as antioxidants and cytotoxic agents. Antioxidants of all the synthesized molecules were evaluated. In addition, four of the compounds were investigated to determine their molecular docking interactions and cytotoxicity. The prepared derivatives exhibited lower antioxidant activity, in comparison with BHA (butylated hydroxy anisole thermolysis).28
Figure 22
ANTICANCER ACTIVITY:
Rambabu Vasamsetti et. al (2025) synthesized and characterized a novel library of imidazole ring incorporated pyridine-1,2,4-oxadiazole compounds (10a-j) and examined their anticancer activities against PC3 and DU-145 (prostate cancer), A549 (lung cancer), MCF-7 (breast cancer)- cell lines using MTT assay with standard drug as etoposide. Compounds 1–14 demonstrated IC50 values of 0.02±0.0047 μM to 10.3 ±5.68μM, whereas etoposide showed values ranging from 1.97±0.45μ M to3.08±0:135μM, respectively. Compounds 5-(5-(pyridin-4-yl)-1,2,4-oxadiazol-3-yl)-N-(2-(5-(3,4,5-trimethoxyphenyl)-1H-imidazol-1-yl) ethyl) pyridin-2 amine Figure 23 were revealed as more active of all.29
Figure 23
Leyla Yurttas et. Al (2023) Synthesis of Certain Novel 1,3,4-Oxadiazole Derivatives and Their Anticancer Activity. Inhibitory activity Figure 24 2-[(5-((2-Acetamidophenoxy) methyl)-1,3,4oxadiazol-2-yl) thio]-N-(6-ethoxybenzothiazol-2yl) acetamide exhibited exceptional antiproliferative effect against C6 cell-line (IC50=8.16μM), while 4h IC50= 13.04μM.30
Figure 24
Anti-Alzheimer’s Disease:
Sana Saffour et. al (2025) Designed, Synthesized In-Vitro and In-Silico Studies of Exploring Novel Quinoline-1,3,4-Oxadiazole Analogues for Alzheimer’s Disease. Out of those synthesized compounds, the compound [(5-((quinolin-8-yloxy) methyl)-1,3,4-oxadiazol-2-y1)thio] acetamide Figure 25 exhibited encouraging activity against AChE with the IC50 values of 0.033 µM, 0.096 µM and 0.177 µM respectively and it is implicated in Alzheimer’ s disease.31
Figure 25
ANTI-DIABETIC ACTIVITY:
Pankaj Kumar et. et al (2022) have synthesized a new series of coumarin fused oxadiazole Schiff base derivatives including PM1-PM10 (3-{5-[(benzylideneamino]-1,3,4-oxadiazol-2-yl}-2H-1-benzopyran-2-one Derivatives)) by reacting the coumarin and oxadiazole amino moieties with various aromatic aldehydes. The synthesized compounds were characterized by IR, Mass and 1 H NMR. In addition, these compounds were also assessed for their ADME properties, molecular docking studies and in-vitro α-glucosidase enzyme inhibition. Compound 3-(5-[(4-hydroxyphenyl) methylidene] amino}-1,3,4-oxadiazol-2-yl)-2H¬ -1-benzopyran-2-one: Figure 26 exhibited the potent antidiabetic activity comparable to that of the standard drug acarbose.32
R=p-OH
Figure 26
Megha Tukaram Salve et. Al (2021) Synthesized, Characterized and Antidiabetic Evaluation of Sulfonamide in Corporated with 1,3,4-Oxadiazole Derivatives Figure 27. Compounds 2-cyano-N-
(oxadiazol-3-yl) pyrrolidine-1-sulfonamide were found to be the most effective in lowering blood glucose, indicating the potential of these compounds as antidiabetic agents.33
Figure 27
Anti-fungal activity:
Iftikhar Ahsan et. Al (2015) Oxadiazole derivatives(4a-d) were synthesized from (2, 4, 5-triphenyl-imidazole -1-yl)-acetic acid hydrazide under different reactions conditions and their antifungal activities compared with those of the standard drug Voriconazole. 1-{[2-(4-chlorophenyl amino)-(1, 3, 4-oxadiazol5-yl)] methyl}-2,4,5-triphenylimidazole Figure 28 behaved moderately (81%) against C. albicans as elaborated by Voriconazole drug.34
Figure 28
Yin Chen et. Al (2015) Many of these studies were successfully replicated in a recent study by Yin Chen et. al (2012) A library of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives Figure 29 has been designed and screened the compounds for their binding affinities at D(2), 5-HT(1A) and 5-HT(2A) receptors. The preliminary pharmacological screening revealed that the 2-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propylthio)-5-(4-methoxyphenyl)-1,3,4-oxadiazole derivatives have high affinities to the D2, 5-HT1A and 5-HT2A receptor for series35
Figure 29
Anti-oxidant activity:
Raied M. Shakir et. al (2014) Synthesis of New 2,5-Di-substituted 1,3,4-Oxadiazoles Bearing 2,6-Di-tert-butylphenol Moieties Figure 30 and Evaluation of Their Antioxidant Activity. The resulting compounds were characterized based on their IR, 1 H-NMR, 13C-NMR, and HRMS data. 2,2-Diphenyl-1-picrylhydrazide (DPPH) and ferric reducing antioxidant power (FRAP) assays were used to test the antioxidant properties of the compounds. Compounds 5f 2,6-Di-tert-butyl-4-(5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl) phenol Figure 25exhibited significant free-radical scavenging ability in both assays.36
Figure 30
Kikkeri N. Mohana et.al (2013) Synthesized and evaluated Antioxidant Activity of 2-Amino-5-methylthiazol Derivatives Containing 1,3,4-Oxadiazole-2-thiol Moiety Figure 31The antioxidant activity of the synthesized compounds was evaluated by 2,2-diphenyl-1-picrylhydrazyl (DPPH), hydroxyl, nitric oxide, and superoxide radical scavenging assay methods. Compounds 5-((2-((2,4-Dimethoxybenzylidene) amino)-5-methylthiazol4-yl) methyl)-1,3,4-oxadiazole-2-thiol 6a showed significant radical scavenging potential due to the presence of electron donating substituent on substituted aldehydes.37
Figure 31
Anti-convulsant:
Mohammad Shaharyar et.al. [2009] synthesized a series of five membered heterocyclics and was tested for convulsion. From the synthesized compounds (IIf) 2-(4-chlorophenyl) amino-5-(4- pyridyl)-1,3,4-thiadiazole and (IIIf) 2-(4-chlorophenyl) amino-5-(4-pyridyl)-1, 3, 4oxadiazole Figure 32 and Figure 33 showed potent activity.38
CONCLUSION:
This review will be a platform for the medicinal chemists to design more potent, efficacious and less toxic 1,3,4-oxadiazole derivatives. This review highlights the design and biological potentials of 1, 3, 4-oxadiazole derivatives. It is apparent from this that such a five-member heterocyclic molecule can be synthesized by different methods and its derivatives exhibited diverse activities. Like anticancer, antimicrobial, anti- inflammatory anti-HIV, antitubercular antidiabetic antifungal etc. Therefore, a study of this molecule helps us to the mankind.
REFERENCES:
1. Arora, P.; Arora, V.; Lamba, H.S.; Wadhwa, D. Importance of heterocyclic chemistry: A contemporary review. Int. J. Pharm. Sci. Res. 2024; 16(9): 3125-3135.
2. Ramawat, KG; Dass, S; Mathur, M The chemical diversity of bioactive molecules and therapeutic potential of medicinal plants: An updated perspective. In: Herbal Drugs: Ethnomedicine to Modern Medicine, 2nd; Springer: Berlin, Heidelberg, 2025; pp. 12-39.
3. Shukla, P.K.; Verma, A.; Mishra, P. Metal complexes of oxadiazole ligands: An overview. Int. J. Mol. Sci. 2019 Jul 16; 20(14): 3483. http://dx.doi.org/10.3390/ijms20143483 PMID: 31315181
4. Kaur, R.; Kaur, P. Synthesis and pharmacological activities of 1, 3, 4-oxadiazole derivatives: A review. Eur J Biomed. 2018; 5(6): 865-877.
5. Omar, A. Review article; Anticancer activities of some fused heterocyclic moieties containing nitrogen and/or sulfur heteroatoms. Al-Azhar J Pharm Sci. 2020; 62(2): 39-54.
6. http://en.wiktionary.org/wiki/oxadiazole, 17 Jan. 2011
7. Sharma S, Sharma P.K, Kumar N, Dudha R, Der Pharma Chemical. 2010; 4: 253-264
8. Bhatia Shivi, Gupta Monika: 1, 3, 4-Oxadiazole as antimicrobial agents: An overview. J. Chem. Pharm. Res. 2011; 3(3): 137-14
9. Boudreau, M. A., Ding, D., Meisel, J. E., Janardhanan, J., Spink, E., Peng, Z., and Chang, M. Structure–activity relationship for the oxadiazole class of antibacterials. ACS Medicinal Chemistry Letters. 2019; 11(3): 322-326.
10. Biernacki, K., Daśko, M., Ciupak, O., Kubiński, K., Rachon, J., & Demkowicz, S. Novel 1, 2, 4-oxadiazole derivatives in drug discovery. Pharmaceuticals. 2020; 13(6): 111.
11. Sulman, A., Afzal, A., Arif, H., Muatter, A., Aamir, Z., Alvi, M. F., & Kharl, H. A. A. Oxadiazole Derivatives: A Comprehensive Review of Their Chemistry, Synthesis, and Pharmacological Potential. Journal of Pharma and Biomedics, 2025; 3(2): 37-50.
12. Kerimov, A.A.; Agabekov, V.E.; Gurbanov, A.V. Synthesis and study of new 1,3,4-oxadiazole derivatives as potential bioactive compounds. J. Heterocycl. Chem., 2020; 57(3): 980-986.
13. Ansari KF, Lal C. Synthesis, physicochemical properties and antimicrobial activity of some new benzimidazole derivatives. Eur J Med Chem. 2009; 44(10): 4028-33. doi: 10. 1016/j.ejmech.2009.04.037, PMID 19482384.
14. Alam, M. M. 1, 3, 4-Oxadiazole as a potential anti-cancer scaffold: A review. Biointerface Research in Applied Chemistry. 2022; 12(4): 5727-5744.
15. Bala, S., Kamboj, S., Kajal, A., Saini, V., and Prasad, D. N. 1, 3, 4‐oxadiazole derivatives: synthesis, characterization, antimicrobial potential, and computational studies. BioMed research international. 2014; 2014(1): 172791.
16. Kumar, H., Javed, S. A., Khan, S. A., and Amir, M. 1, 3, 4-Oxadiazole/thiadiazole and 1, 2, 4-triazole derivatives of biphenyl-4-yloxy acetic acid: synthesis and preliminary evaluation of biological properties. European Journal of Medicinal Chemistry. 2008; 43(12): 2688-2698.
17. Shashikant, V., Kailash, G. B., Mayuresh, K. R., Ajit, A. P., Aniket, P. S., and Vinod, J. M. Design, Synthesis and Evaluation of Anti-inflammatory, Analgesic and Ulcerogenicity studies of Novel S-Substituted phenacyl-1, 3, 4-oxadiazole-2-thiol and Schiff bases of Diclofenac acid as Nonulcerogenic Derivatives. Bioorg Med Chem. 2008; 16(4): 1822-31.
18. Jayashankar, B., Rai, K. L., Baskaran, N., and Sathish, H. S.. Synthesis and pharmacological evaluation of 1, 3, 4-oxadiazole bearing bis (heterocycle) derivatives as anti-inflammatory and analgesic agents. European Journal of Medicinal Chemistry. 2009; 44(10): 3898-3902.
19. Rathore, A., Rahman, M. U., Siddiqui, A. A., Ali, A., and Shaharyar, M. Design and synthesis of Benzimidazole analogs endowed with oxadiazole as selective COX‐2 inhibitor. Archiv der Pharmazie. 2014; 347(12): 923-935.
20. Husain, A., and Ajmal, M. (). Synthesis of novel 1, 3, 4-oxadiazole derivatives and their biological properties. Acta Pharmaceutica. 2009; 59(2): 223-233.
21. Rajak, H., Veerasamy, R., Kharya, M., and Mishra, P. Design, synthesis, and pharmacological evaluation of novel oxadiazole and oxadiazoline analogs as anti-inflammatory agents. Journal of Enzyme Inhibition and Medicinal Chemistry. 2010; 25(4): 492-501.
22. Thakkar, S. S., Thakor, P., Doshi, H., and Ray, A. 1, 2, 4-Triazole and 1, 3, 4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities. Bioorganic & Medicinal Chemistry. 2017; 25(15): 4064-4075.
23. Dunga, A. K., Allaka, T. R., Kethavarapu, Y., Nechipadappu, S. K., Pothana, P., Ravada, K., and Kishore, P. V. Design, synthesis and biological evaluation of novel substituted indazole-1, 2, 3-triazolyl-1, 3, 4-oxadiazoles: antimicrobial activity evaluation and docking study. Results in Chemistry. 2022; 4: 100605.
24. Shridhar, A. H., Keshavayya, J., Peethambar, S. K., Hoskeri, H. J. Synthesis and biological activities of Bis alkyl 1, 3, 4-oxadiazole incorporated azo dye derivatives. Arabian Journal of Chemistry. 2016; 9: S1643-S1648.
25. Alatawi, K., Qarah, A. F., Alharbi, H., Alisaac, A., Abualnaja, M. M., Attar, R. M., and El-Metwaly, N. M. Synthesis of designed new 1, 3, 4-oxadiazole functionalized pyrano [2, 3-f] chromene derivatives and their antimicrobial activities. Heliyon. 2024; 10(19).
26. Ryad, N., Elmaaty, A. A., Selim, S., Almuhayawi, M. S., Al Jaouni, S. K., Abdel-Aziz, M. S., and Ghany, L. M. A. Design and synthesis of novel 2-(2-(4-bromophenyl) quinolin-4-yl)-1, 3, 4-oxadiazole derivatives as anticancer and antimicrobial candidates: in vitro and in silico studies. RSC Advances. 2024; 14(46): 34005-34026.
27. Manjunath, R., Anantharaju, P. G., Madhunapantulas, S. V., and Gaonkar, S. L. Design, synthesis, and biological evaluation of 2-butyl-4-chloroimidazole-derived 1, 3, 4-oxadiazoles: ACE inhibition, anticancer, and antitubercular activities. Journal of Molecular Structure. 2025; 1322: 140630.
28. Shiferaw, D. G., and Kalluraya, B. Synthesis, characterization, biological evaluation, and molecular docking studies of new 1, 3, 4-oxadiazole-thioether derivative as antioxidants and cytotoxic agents. Heliyon. 2024; 10(7).
29. Vasamsetti, R., Gatchakayala, N. B., Bujjibabu, N., Kumar, V. S., Satyanarayana, T. V. V., Pavani, G., and Madhav, B. Rational design, and synthesis of imidazole ring incorporated Pyridine-1, 2, 4-oxadiazole derivatives: In-vitro anticancer evaluation and in-silico molecular docking simulations. Results in Chemistry. 2025; 15: 102217.
30. Yurttaş, L., Evren, A. E., Kubilay, A., Aksoy, M. O., Temel, H. E., and Akalın Çiftçi, G. Synthesis of some new 1, 3, 4-oxadiazole derivatives and evaluation of their anticancer activity. ACS Omega. 2023; 8(51): 49311-49326.
31. Saffour, S., Evren, A. E., Saglik, B. N., and Yurttas, L. Exploring novel quinoline-1, 3, 4-oxadiazole derivatives for Alzheimer’s disease: their design, synthesis, and in-vitro and in-silico investigations. Current Medicinal Chemistry. 2025; 32(21): 4259-4283.
32. Kumar, P., Kumar, A., Maziyuna, F. A., Bhat, N., and Mulukuri, N. S. Design, synthesis, and antidiabetic evaluation of coumarin fused oxadiazole derivatives. Rasayan Journal of Chemistry. 2022; 15(4).
33. Salve, M. T., and Jadhav Sr, S. B. Synthesis, characterization and antidiabetic evaluation of sulfonamide in corporated with 1, 3, 4-oxadiazole derivatives. Indian J. Pharm. Educ. Res. 2021; 55: 1145-1150.
34. Iftikhar Ahsan, I. A., and Chandrul, K. K. Antimicrobial and antifungal evaluation of newly synthesized oxadiazole derivatives bearing 2, 4, 5-triphnenyl imidazole moiety. 2015
35. Chen, Y., Xu, X., Liu, X., Yu, M., Liu, B. F., and Zhang, G. Synthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1, 3, 4-oxadiazoles derivatives as atypical antipsychotics. PLoS One. 2012; 7(4): e35186.
36. Shakir, R. M., Ariffin, A., and Abdulla, M. A. Synthesis of new 2, 5-di-substituted 1, 3, 4-oxadiazoles bearing 2, 6-di-tert-butylphenol moieties and evaluation of their antioxidant activity. Molecules. 2014; 19(3): 3436-3449.
37. Mohana, K. N., and Kumar, C. B. P. Synthesis and Antioxidant Activity of 2‐Amino‐5‐methylthiazol Derivatives Containing 1, 3, 4‐Oxadiazole‐2‐thiol Moiety. International Scholarly Research Notices. 2013; 2013(1): 620718.
38. Mohammad Shaharyar, Mohammad Wasim Akhter, Acta Poloniae Pharmaceutica n Drug Research. 2009; 66(4): 393-397.
|
Received on 21.01.2026 Revised on 02.04.2026 Accepted on 12.05.2026 Published on 10.10.2026 Available online from October 17, 2026 Asian J. Pharm. Res. 2026; 16(4):461-469. DOI: 10.52711/2231-5691.2026.00067 ©Asian Pharma Press All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|